

## FACULTY

Abu Rumeileh Imad, Radioterapia Oncologica, Azienda Ulss3 Serenissima, Venezia Mestre

Azzarello Giuseppe, Ematologia e Oncologia, Ulss3 Serenissima Dolo/Mirano

Bearz Alessandra, Oncologia Medica, CRO AVIANO

Bonanno Laura, Oncologia Medica 2 IOV-IRCCS, Padova

Borghetti Paolo, Radioterapia, Spedali Civili Brescia

Breda Cristiano, Chirurgia Toracica, Azienda Ulss3 Serenissima, Venezia Mestre

Bruni Alessio, Radioterapia, Azienda Ospedaliero-Universitaria di Modena

Ciammella Patrizia, Radioterapia Oncologica "G. Prodi" AUSL-IRCCS di Reggio Emilia

Ferrari Katia, Pneumologia, Azienda Ospedaliero-Universitaria Careggi di Firenze

Giaj Levra Niccolò, Radioterapia, IRCCS Ospedale Sacro Cuore Don Calabria Negrar (VR)

Krengli Marco, Radioterapia, IOV-IRCCS, Padova

Michieletto Lucio, Pneumologia, Azienda Ulss3 Serenissima, Venezia Mestre

Morandi Paolo, Oncologia, Azienda Ulss3 Serenissima, Venezia Mestre

Nicolè Lorenzo, Anatomia Patologica Azienda Ulss3 Serenissima Venezia Mestre

Pavan Alberto, Oncologia, Azienda Ulss3 Serenissima, Venezia Mestre

Rampin Lucia, Medicina Nucleare, Azienda Ulss3 Serenissima, Venezia Mestre

Rapicetta Cristian, Chirurgia Toracica, AUSL-IRCCS di Reggio Emilia

Rosetti Francesco, Oncologia Medica, Azienda Ulss3, Chioggia

Sartori Paolo, Radiologia, Azienda Ulss3 Serenissima, Venezia

Scricciolo Melissa, Radioterapia Oncologica, Ulss3 Serenissima, Venezia Mestre

Trovò Marco, Radioterapia, Azienda Sanitaria Universitaria Integrata, Udine

Vagge Stefano, Radioterapia, Ente Ospedaliero Ospedali Galliera di Genova

Zustovich Fable, Oncologia, Ulss1 Dolomiti, Belluno

## UNDER THE AUSPICES OF



Associazione Italiana  
Radioterapia e Oncologia clinica



## WITH THE UNCONDITIONAL CONTRIBUTION OF



## SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER:



Events srl  
Via Lorenzo Lotto 9  
60019 Senigallia (AN)  
Tel. 071-7930220  
www.events-communication.com  
segreteria4@events-communication.com



22  
SETTEMBRE  
2023

# NSCLC

## STATE OF THE ART AND NOVEL THERAPEUTIC APPROACHES

RESPONSABILE SCIENTIFICO  
**Melissa Scricciolo**



VENEZIA



## RATIONALE

The treatment of non-small cell lung cancer (NSCLC) is a challenging setting that have to be approached in a multidisciplinary team for an adequate staging, personalized treatment and toxicity management of the patient. Anatomical resection and systematic lymph node dissection is the recommended treatment for early-stage NSCLC (non-small cell lung cancer). Stereotactic body radiotherapy (SBRT) is an alternative for non-operable patients. Locally advanced NSCLC (non-small cell lung cancer) could be treated with a combination of chemotherapy, radiotherapy and immunotherapy, and in selected cases followed by surgical resection. Treatment for patients with metastasized NSCLC (non-small cell lung cancer) depends on molecular tumor characteristics, PD-L1 expression and could consist of chemotherapy, immunotherapy, targeted therapy or a combination of these modalities. Because of the success of immunotherapy and targeted therapy for stage IV NSCLC (non-small cell lung cancer), numerous trials have started to investigate the efficacy of these modalities in early-stage NSCLC (non-small cell lung cancer) as well, further optimizing treatment strategies for this patient group. In this meeting we will discuss the diagnostic workup and current treatment strategies for NSCLC (non-small cell lung cancer) for each stage.

## OFFICIAL LANGUAGE

The official language is Italian

## SCIENTIFIC COMMITTEE CHAIR

**Melissa Scricciolo**, Radioterapia Oncologica, Ulss3 Serenissima, Venezia Mestre

## SCIENTIFIC COMMITTEE

**Melissa Scricciolo, Imad Abu Rumeileh, Michele Antonello**

## CME CREDITS

CME accredited only for on site participants

The course is accredited for: Dietitian, Physicians (Disciplines: Radiotherapy, Oncology, Radiology, Thoracic surgery, Pneumology, Nuclear medicine), Medical Physicist, Nurse, Psychologist, Radiotherapist, Radiographer (TSRM).

CME credits: 5 - ID event: 381971

Italian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality and duly fill in the evaluation questionnaires answering correctly 75% of the questions.

Free registration here:

[www.events-communication.com/nsclc2023](http://www.events-communication.com/nsclc2023)

To attend the event online and without CME accreditation, free registration here:

<https://us02web.zoom.us/j/82091881242>

## VENUE

**Ospedale SS Giovanni e Paolo a Venezia**

Sala San Domenico  
Sestiere Castello, 6777, 30122 Venezia

# SCIENTIFIC PROGRAM

- 09:15 Registration of participants
- 09:30 Welcome of elected president of AIRO - **M. KRENGLI**
- 09:40 Introduction and greetings - **I. ABU RUMEILEH, M. SCRICCIOLO**

## SESSION 1

### DIAGNOSIS AND STAGING IN THE MULTIDISCIPLINARY TEAM SETTING

Moderators: **M. SCRICCIOLO, G. AZZARELLO**

- 09:45 The role of Radiologist: providing key information for clinicians - **P. SARTORI**
- 10:05 The role of Nuclear physician: providing key information for clinicians - **L. RAMPIN**
- 10:20 The role of Pulmonologist:  
- the clinical approaches - **K. FERRARI**  
- the invasive approaches (EBUS\TBNA and Mediastinoscopy) - **L. MICHIELETTO**
- 10:50 Histopathological diagnosis and molecular testing - **L. NICOLÈ**
- 11:05 Management of patients in the teamwork of ULSS3 - **I. ABU RUMEILEH**
- 11:20 Questions and remarks
- 11:35 **Coffee break**

## SESSION 2

### UPDATE AND FORECAST IN TREATMENT OF EARLY STAGE NSCLC

Moderators: **M. TROVÒ, F. ZUSTOVICH**

- 12:05 Surgical issues for operable early stage NSCLC - **C. BREDA**
- 12:20 SBRT: current standards and ongoing research - **S. VAGGE**
- 12:35 The rationale for systemic therapy: right drugs, right patients, right time? - **A. BEARZ**
- 12:50 Questions and remarks
- 13:05 **Lunch**

## SESSION 3

### UPDATE AND FORECAST IN TREATMENT OF LOCALLY ADVANCED NSCLC

Moderators: **A. BRUNI, F. ROSETTI**

- 14:05 Which patient is eligible for surgery? - **C. RAPICETTA**
- 14:15 The role of Radiation Oncologist: volumes, doses, risk toxicity - **P. CIAMMELLA**
- 14:35 The role of Medical oncologist: systemic therapy and risk toxicity - **L. BONANNO**
- 14:50 Diagnosis and management of lung toxicity in local and systemic therapies: the role of Pulmonologist - **K. FERRARI**
- 15:05 Questions and remarks

## SESSION 4

### UPDATE AND FORECAST IN TREATMENT OF METASTATIC/OLIGOPROGRESSIVE NSCLC

Moderators: **P. BORGHETTI, P. MORANDI**

- 15:20 The role of Medical oncologist: systemic/target therapy and risk toxicity - **A. PAVAN**
- 15:40 The role of Radiation Oncologist- **N. GIAJ LEVRA**
- 15:55 Questions and remarks
- 16:10 Closure

